Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery

Journal of Controlled Release

Volumn 143, Issue 1, 2010, Pages 38-44

  Eisenbrey, J R ^a   Burstein, O Mualem ^a   Kambhampati, R ^a   Forsberg, F ^b   Liu, J B ^b   Wheatley, M A ^a  

^a DREXEL UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Double emulsion; Doxorubicin; Drug loaded; Echogenicity; Poly(lactic acid); Ultrasound contrast agents

Indexed keywords

DOUBLE EMULSIONS; DOXORUBICIN; ECHOGENICITY; POLY(LACTIC ACID); ULTRASOUND CONTRAST AGENT;

BODY FLUIDS; DRUG DELIVERY; EMULSIFICATION; ENCAPSULATION; LACTIC ACID; MORPHOLOGY; ORGANIC ACIDS; ULTRASONIC TRANSMISSION;

ULTRASONICS;

DOXORUBICIN; POLYLACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TISSUE LEVEL; ECHOGRAPHY; ENCAPSULATION; IMAGING; IN VITRO STUDY; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; CHEMISTRY, PHARMACEUTICAL; CONTRAST MEDIA; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; HALF-LIFE; INJECTIONS, INTRAVENOUS; KIDNEY; KINETICS; LACTIC ACID; MICROSCOPY, CONFOCAL; PARTICLE SIZE; POLYMERS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; ULTRASONICS; ULTRASONOGRAPHY, DOPPLER, PULSED;

EID: 77950519661     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.12.021     Document Type: Article

References (28)

1. Singal P., Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl. J. Med. 1998, 339:900-905.
2. Alberts D.S., Garcia D.J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997, 54:30-35.
3. Goram A.L., Richmond P.L. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy 2001, 21:751-763.
4. Hoff L. Acoustic properties of ultrasonic contrast agents. Ultrasonics 1996, 34:591-593.
5. Goldberg B.B., Raichlen J.S., Forsberg F. Ultrasound contrast agents: basic principles and clinical applications 2001, Martin Dunitz, London. second edition.
6. Unger E.C., Matsunaga T.O., McCreery T., Schumann P., Sweitzer R., Quigley R. Therapeutic applications of microbubbles. Eur. J. Radiol. 2002, 42:160-168.
7. Judson I., Radford J.A., Harris M., et al. Randomized phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2001, 37:870-877.
8. O'Brien M.E., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449.
9. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997, 15:987-993.
10. Tan E.C., Lin R., Wang C.H. Fabrication of double-walled microspheres for the sustained release of doxorubicin. J. Colloid Interface Sci. 2003, 291:135-143.
11. Husseini G.A., de la Rosa M.A.D., Gabuji T., et al. Release of doxorubicin from unstabilized and stabilized micelles under the action of ultrasound. J. Nanosci. Nanotechnol. 2007, 7:1028-1033.
12. Gao Z.G., Fain H.D., Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release 2005, 102:203-222.
13. I. Lentacker, B. Geers, J. Demeester, S.C. De Smedt, N.N. Sanders, Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved, Mol. Ther. 18 (2010) 101-108.
14. Kooiman K., Böhmer M.R., Emmer M., et al. Oil-filled polymer microcapsules for ultrasound-mediated delivery of lipophilic drugs. J. Control. Release 2009, 133:109-118.
15. Shi W.T., Böhmer M., van Wamel A., et al. Ultrasound therapy with drug loaded microcapsules. IEEE Ultrasonics Symposium 2007, 773-776.
16. El-Sherif D.M., Wheatley M.A. Development of a novel method for synthesis of a polymeric ultrasound contrast agent. J. Biomed. Mater. Res. A. 2003, 66:347-355.
17. Wheatley M.A., Lathia J.D., Oum K.L. Polymeric ultrasound contrast agents targeted to integrins: importance of process methods and surface density of ligands. Biomacromolecules. 2007, 8:516-522.
18. J.R. Eisenbrey, M.C. Soulen, M.A. Wheatley, Delivery of Encapsulated Doxorubicin by Ultrasound Mediated Size Reduction of Drug Loaded Polymer Contrast Agents, IEEE TBME Letters. (in Press) (Special Issue on Emerging Technologies in Therapeutic Ultrasound).
19. Eisenbrey J.R., Huang P.N., Soulen M.C., et al. Doxorubicin loaded contrast agents for ultrasound triggered drug delivery: importance of process parameters. Pharm. Eng. 2008, 28:70-78.
20. Wheatley M.A., Forsberg F., Oum K.L., et al. Comparison of in vitro and in vivo acoustic response of a novel 50:50 PLGA contrast agent. Ultrasonics 2006, 44:360-367.
21. Forsberg F., Lathia J.D., Merton D.A., et al. Effect of shell type on the in vivo backscatter from polymer-encapsulated microbubbles. Ultrasound Med. Biol. 2004, 30:1281-1287.
22. Lentacker I., De Smedt S.C., Sander N.N. Drug loaded microbubble design for ultrasound triggered delivery. Soft Matter. 2009, 5:2161-2170.
23. Miyazaki S., Hou W.M., Takada M. Controlled drug release by ultrasound irradiation. Chem. Pharm. Bull. 1985, 33:428-431.
24. Wu J., Nyborg W.L. Ultrasound, cavitation bubbles and their interaction with cells. Adv. Drug Del. Rev. 2008, 60:1103-1116.
25. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv. Drug Del. Rev. 2008, 60:1193-1208.
26. Postema M., Schmitz G. Ultrasonic bubbles in medicine: influence of the shell. Ultrason. Sonochem. 2007, 15:438-444.
27. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat. Rev. Drug Discov. 2005, 4:255-260.
28. Eisenbrey J.R., Huang P.N., Hsu J., et al. Ultrasound triggered cell death in vitro with doxorubicin loaded poly lactic-acid contrast agents. Ultrasonics 2009, 49:628-633.